This document updates the 2009 ECDC guidance on chlamydia control in Europe. It was developed by a technical expert group which conducted a critical review of the scientific evidence on the epidemiology of chlamydia and the effectiveness of screening programmes.
The aim of this guidance is to suppo...rt Member States to develop, implement or improve strategies for chlamydia control. This guidance describes the current evidence base behind the proposed options, highlights key gaps in knowledge, and suggests effective options for national chlamydia control strategies. It is directed primarily at policy advisors but should also be useful for programme managers and experts in sexual health.
more
Infection prevention and control measures for Ebola virus disease
ECDC Technical Report
In line with ECDC’s recommendations provided in the ’Risk Assessment of HTLV-1/2 transmission by tissue/cell transplantation’ dated 14 March 2012, this Directive replaces the term ‘incidence’ with ‘prevalence’ in the description of endemic areas of HTLV-1/2 i...nfection. According to the new requirements ‘HTLV-1 antibody testing must be performed for donors living in, or originating from high-prevalence areas or with sexual partners originating from those areas or where the donor’s parents originate from those areas’ and this applies to both donors of non-reproductive tissues and cells and reproductive cells.
ECDC contracted experts from the Institut Pasteur in Paris to systematically review the published evidence on the distribution of HTLV-1 infection prevalence throughout the world and to identify high-prevalence countries and areas.
more
This document provides guidance on the application of non-pharmaceutical countermeasures to minimise the spread of the 2019 novel coronavirus (2019-nCoV) in the population. Some of the measures proposed refer specifically to certain phases of the epidemic (containment or mitigation phases), and can ...be adapted depending on the assessed severity/impact of the infection. Other measures are valid for all phases of an epidemic.
The guidance is based on the current knowledge of the 2019-nCoV and evidence available on other viral respiratory pathogens, mainly the Severe Acute Respiratory Syndrome coronavirus (SARS-CoV), the Middle East Respiratory Syndrome-related coronavirus (MERS-CoV) and seasonal or pandemic influenza viruses.
more
The Suicide Prevention Resource Center (SPRC) has compiled a selection of web pages and information sheets
on mental health and coping with the effects of COVID-19. These resources are a selection from key organizations
in the field. We will continue to update this list as new resources become ava...ilable.
more
Non-pharmaceutical interventions (NPI) are public health measures that aim to prevent and/or control SARS-CoV-2 transmission in the community. As long as there is no effective and safe vaccine to protect those at risk of severe COVID-19, NPI are the most effective public health interventions against... COVID-19. These ECDC guidelines detail available options for NPI in various epidemiologic scenarios, assess the evidence for their effectiveness and address implementation issues, including potential barriers and facilitators.
more
Vous avez appris, il y a peu de temps ou peut-être plus, que vous étiez séropositif·ve.
Peut-être vous attendiez-vous un peu à ce résultat, peut-être pas du tout. Vous avez peut-être ressenti un
choc à cette annonce, et une foule de questions vous sont venues.
Cette brochure a pour bu...t de répondre à certaines d’entre elles et, en abordant différents aspects, de vous
aider petit à petit à apprivoiser votre nouvelle situation.
Les avancées médicales ont été extrêmement importantes ces dernières années, tant au niveau des traitements qu’au niveau des stratégies de prévention. Avec des conséquences concrètes. Les personnes vivant
avec le VIH sont aujourd’hui considérées comme des patient·es atteint·es d’une maladie chronique, avec laquelle on peut vivre de très nombreuses années, pour autant que l’on prenne correctement son traitement.
more
Biosafety involves the implementation of containment principles, technologies and practices to prevent unintentional exposure to biological agents. Biosecurity involves the protection, control and accountability of biological materials and information related to these materials and dualuse research,... to prevent their unauthorized access, loss, theft, misuse, diversion or intentional release.
more
5 April 2022, Addendum. This policy brief confirms WHO guidance and policy on injection safety in the context of the extraordinary increase in global injections resulting from COVID-19 immunization campaigns. It also calls attention to information on specialized syringes for COVID-19 vaccines and br...oad short-term and long-term solutions to address and alleviate supply shortages related to vaccine products with non-standard dose volumes.
more
This report provides an overview of the main findings of the 2019–2020 harmonised AMR monitoring in the main food-producing animal populations monitored, in carcase/meat samples and in humans. Where available, monitoring data obtained from pigs, calves, broilers, laying hens and turkeys, as well a...s from carcase/meat samples and humans were combined and compared at the EU level, with particular emphasis on multidrug resistance, complete susceptibility and combined resistance patterns to critically important antimicrobials, as well as Salmonella and E. coli isolates possessing ESBL-/AmpC-/carbapenemase phenotypes.
more
Africa CDC Institute of Pathogen Genomics (IPG) was launched in November 2019 and operates under the Division of Laboratory Systems and Networks.
IPG coordinate the implementation of molecular diagnostics, pathogen genomics and bioinformatics in National Public Health Institutions (NPHIs) and/or Re...fe-
-rence Laboratories (NRLs) across Africa.
Africa CDC and APHF are coordinating a continental initiative to maximize the benefits of molecular approaches and pathogen genomics for more effective
outbreak preparedness, prevention, response, and for the control and elimination of endemic diseases in Africa. One of Africa CDC’s flagship initiative is the Africa
Pathogen Genomics Initiative (Africa PGI), a partnership that aims to strengthen laboratory systems and enhance genomic surveillance by equipping the continent’s
public health institutions with the tools, training, and data infrastructure.
About the Project
In 2023, 166 outbreaks and public health events were reported in Africa. This calls for a resilient laboratory systems for timely detection and reporting of current and future outbreaks. This project aims to scale up molecular diagnostic and genomic sequencing-based detection and characterization of outbreaks.
Africa CDC is working with Member States to develop guidance, diagnostic algorithm, training and capacity building to enable outbreak detection, and reporting to inform public health response.
more
The monkeypox virus (MPXV) clade I epidemic that has been affecting the Democratic Republic of the Congo
(DRC) since November 2023 has recently spread to several other African countries including Burundi, Rwanda,
Uganda and Kenya. The size of these outbreaks could be larger than reported due to un...der-ascertainment and
under-reporting.
more
This threat assessment addresses the implications of the ongoing Marburg virus disease (MVD) outbreak in
Rwanda for the European Union/European Economic Area (EU/EEA). MVD is a severe disease in humans and,
although uncommon, it has the potential to cause epidemics with significant case fatality. ...All recorded MVD
outbreaks to date have originated in Africa. MVD is not an airborne disease and is considered not to be
contagious before symptoms appear. Direct contact with the blood and other body fluids of infected people
and animals or indirect contact with contaminated surfaces and materials like clothing, bedding and medical
equipment is required for transmission. The risk of infection is minimised when proper infection prevention and
control precautions are strictly followed. There is no approved treatment or vaccine for MVD; however, several
pharmaceuticals and candidate MVD vaccines are under investigation.
more
Marburg virus disease (MVD), formerly known as Marburg haemorrhagic fever, is a severe disease in humans caused by Marburg marburgvirus (MARV). Although MVD is uncommon, MARV has the potential to cause epidemics with significant case fatality rates.
Preparedness planning is essential in order to respond effectively to outbreaks, including single case occurrences of highconsequence infectious diseases (HCID), such as the importation of a viral haemorrhagic fever (VHF) case